MTEM vs. FBIO, BOLT, ERNA, GHSI, ABVC, MIRA, MBRX, CMMB, ATHE, and AEZS
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Eterna Therapeutics (ERNA), Guardion Health Sciences (GHSI), ABVC BioPharma (ABVC), MIRA Pharmaceuticals (MIRA), Moleculin Biotech (MBRX), Chemomab Therapeutics (CMMB), Alterity Therapeutics (ATHE), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.
Fortress Biotech (NASDAQ:FBIO) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
In the previous week, Fortress Biotech had 9 more articles in the media than Molecular Templates. MarketBeat recorded 14 mentions for Fortress Biotech and 5 mentions for Molecular Templates. Molecular Templates' average media sentiment score of 0.46 beat Fortress Biotech's score of -0.09 indicating that Fortress Biotech is being referred to more favorably in the media.
Molecular Templates has lower revenue, but higher earnings than Fortress Biotech. Molecular Templates is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Molecular Templates has a net margin of -57.92% compared to Molecular Templates' net margin of -69.13%. Molecular Templates' return on equity of -770.86% beat Fortress Biotech's return on equity.
96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 95.5% of Molecular Templates shares are owned by institutional investors. 33.4% of Fortress Biotech shares are owned by insiders. Comparatively, 13.4% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Fortress Biotech has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
Fortress Biotech presently has a consensus price target of $30.00, suggesting a potential upside of 1,438.46%. Given Molecular Templates' higher possible upside, equities research analysts plainly believe Fortress Biotech is more favorable than Molecular Templates.
Molecular Templates received 18 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 64.80% of users gave Fortress Biotech an outperform vote.
Summary
Fortress Biotech beats Molecular Templates on 12 of the 17 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Templates Competitors List
Related Companies and Tools
